Insight

Naval Daver presents findings of the ENHANCE-3 study at EHA2024 – AML Hub

Photo taken from AML Hub/X

Jun 19, 2024, 07:28

Naval Daver presents findings of the ENHANCE-3 study at EHA2024 – AML Hub

AML Hub shared the following post on X: .

“CONGRESS EHA2024 | Naval Daver

MD Anderson Cancer Center presents findings of the phase III ENHANCE-3 study (NCT05079230) evaluating efficacy and safety of magrolimab (vs placebo) in combination with azacitidine and venetoclax in pts with previously untreated AML ineligible for IC (N=378). Magrolimab, in comparison with placebo, led to:

longer mOS (10.7 vs 14.1 mo, respectively),
more deaths (44.4% vs 37.0%, respectively),
similar CR rate within 6 cycles of treatment (41.3% vs 46.0%, respectively), and
increased incidence of fatal AEs (19% vs 11.4%, respectively) and infections (11.1% vs 6.5%, respectively).

The study was stopped early due to crossing the prespecified futility boundary for OS.”

Naval Daver presents findings of the ENHANCE-3 study at EHA2024 - AML Hub

Source: AML Hub/X

AML Hub azacitidine cancer CONGRESS EHA2024 CR rate efficacy fatal AEs futility boundary ineligible for IC infections magrolimab MD Anderson Cancer Center mOS Naval Daver NCT05079230 OncoDaily Oncology phase III ENHANCE-3 study safety untreated AML venetoclax

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology